Newsroom
PRESS RELEASE
Apmonia Therapeutics announces the launch of the THROMBOTAX program with the support of the ANR
(French National Research Agency)
Apmonia Therapeutics’ technology platform, specialized in the therapeutic targeting of the extracellular matrix, shows strong potential in the field of cardiovascular pathologies and thrombosis Reims,
février 6, 2023
OVERALL NEWS
ATVB
Towards the Therapeutic Use of Thrombospondin 1/CD47 Targeting TAX2 Peptide as an Antithrombotic Agent. Download PDF
janvier 23, 2023